Abstract
We followed 21 patients with sensory neuronopathy without evidence of cancer for up to 23 years. All were seronegative for type 1 antineuronal nuclear antibodies (ANNA-1, also called "anti-Hu"). We additionally studied 67 seropositive patients with sensory neuronopathy or a related neurologic syndrome. Ninety-one percent of the seropositive patients had a small-cell lung carcinoma. One, with a normal chest x-ray, had been followed for 7 years for sensory neuronopathy of indeterminate cause before serologic testing for ANNA-1 led to the discovery of the tumor by CT. We conclude that ANNA-1 seropositivity in a patient with sensory neuronopathy is strong evidence for an underlying small-cell lung cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 2209-2211 |
Number of pages | 3 |
Journal | Neurology |
Volume | 43 |
Issue number | 11 |
State | Published - Nov 1993 |
ASJC Scopus subject areas
- Clinical Neurology